Research company Curasight is carrying out a directed share issue of approximately DKK 20 million before issue costs. The company is issuing 1.12 million shares at a subscription price of DKK 17.80 per share, corresponding to a discount of approximately 10.3 percent compared with the volume-weighted average price since the beginning of May.The capital will be used to strengthen working capital and finance the continued clinical development of uTRACE and uTREAT through the end of the first half of 2027. At the same time, the company has renegotiated its loan from Fenja Capital. The maturity date for the outstanding loan of approximately DKK 36 million is extended to 30 June 2027 from 29 December this year.The issue entails dilution of approximately 2.3 percent for existing shareholders who do not participate.